Results 21 to 30 of about 4,771 (191)

RETRACTED ARTICLE: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer [PDF]

open access: yesJournal of Cancer Research and Clinical Oncology, 2013
Purpose Advanced thyroid cancer responds poorly to most therapies. New therapies and combinations are needed. The aim of this study was to examine both in vitro and in vivo activity of two relatively new histone deacetylase inhibitors (HDACIs ...
Daniel Chan   +8 more
doaj   +5 more sources

Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report

open access: yesClinical Case Reports
Angioimmunoblastic T‐cell lymphoma (AITL), a rare and aggressive subtype of peripheral T‐cell lymphoma (PTCL), often demonstrates resistance to standard therapies.
Vassiliki Labropoulou   +6 more
doaj   +2 more sources

Repurposing Belinostat for Alleviation of Atopic Dermatitis [PDF]

open access: yesDermatology and Therapy, 2021
Atopic dermatitis (AD) is a highly prevalent chronic inflammatory skin disease that is characterized by intense pruritus, seriously affecting patients' quality of life. Its pathophysiology, which involves both the adaptive and innate immune responses as well as skin barrier defects, is still poorly understood. We recently identified a microRNA, miR-335,
Shan Quah   +2 more
openaire   +2 more sources

Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer

open access: yes, 2023
Purpose: The histone deacetylase inhibitor (HDACi), belinostat, has had limited therapeutic impact in solid tumors, such as colon cancer, due to its poor metabolic stability. Here we evaluated a novel belinostat prodrug, copper-bis-belinostat (Cubisbel),
Anna Blümel (7898387)   +19 more
core   +5 more sources

Drug Monographs: Belinostat and Idelalisib [PDF]

open access: yesHospital Pharmacy, 2014
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases ...
Whitney L, Piper   +2 more
openaire   +2 more sources

Apoptotic effect of Belinostat [PDF]

open access: yes, 2021
Aim: Breast cancer continues to be the most common type of cancer among women. Recent development in epigenomics has highlighted key mechanisms in which epigenetic regulation contributes to cancer treatment.
Eroglu Gunes, Canan   +3 more
core   +1 more source

Anticancer clinical efficiency and stochastic mechanisms of belinostat

open access: yesBiomedicine & Pharmacotherapy, 2023
Cancer progression is strongly affected by epigenetic events in addition to genetic modifications. One of the key elements in the epigenetic control of gene expression is histone modification through acetylation, which is regulated by the synergy between histone acetyltransferases (HATs) and histone deacetylases (HDACs).
Nasreddine El Omari   +8 more
openaire   +2 more sources

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo

open access: yesJournal of Translational Medicine, 2007
Background Treatment options for patients with recurrent superficial bladder cancer are limited, necessitating aggressive exploration of new treatment strategies that effectively prevent recurrence and progression to invasive disease.
Liebes Leonard   +10 more
doaj   +1 more source

Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report

open access: yesClinical Case Reports, 2023
Key Clinical Message This case report highlights the potential of belinostat for the treatment of relapsed/refractory peripheral T‐cell lymphomas, for which effective therapies are still scarce.
Vincent Camus   +16 more
doaj   +1 more source

Retraction Note: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer [PDF]

open access: yesJournal of Cancer Research and Clinical Oncology
Daniel Chan   +8 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy